drugset
drugset / Trial / NCT00215566

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c

NCT00215566 ↗

Phase 2 Completed 90 enrolled Dynogen Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety, tolerability and pharmacodynamics of the investigational drug DDP733 in treating subjects with IBS-c. A placebo control will be utilized.

Timeline

Start
2005-09
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject DDP733 Unknown — —

Indications

irritable bowel syndrome